Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.54 |
| ▸ | RORC | P51449 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138925 | 0.89 | EPHX2 (0.59) | CYP17A1NAMPTLMNAHTTEPHX2 | |
| SCHEMBL1854209 | 0.85 | ATM (0.56) | CYP17A1NAMPTSMN1; SMN2PPARGPPARA | |
| SCHEMBL6718330 | 0.83 | MTOR (0.49) | CYP17A1MTORLMNAHTTEPHX2 | |
| SCHEMBL30929531 | 0.82 | EPHX2 (0.51) | CYP17A1NAMPTLMNAHTTEPHX2 | |
| SCHEMBL28095339 | 0.82 | CYP17A1 (0.54) | CYP17A1NAMPTMAPTMEN1KMT2A | |
| SCHEMBL4574985 | 0.81 | LSS (0.52) | MTORNAMPTEPHX2L3MBTL1HDAC1 | |
| SCHEMBL17687214 | 0.81 | PHGDH (0.46) | MTORNAMPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL25688378 | 0.81 | CYP17A1 (0.53) | CYP17A1NAMPTHDAC1HDAC6PPARG | |
| SCHEMBL30741277 | 0.80 | KCNQ2 (0.49) | CYP17A1RORCMTORLMNAHTT | |
| SCHEMBL23336325 | 0.80 | CYP17A1 (0.62) | CYP17A1NAMPTMAPTHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-7592477-B2 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2009-09-22 | — | — | US | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
| EP-1470102-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003064376-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | CYP17A1 488/4885RORC 3420/4885MTOR 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.